22 May 2019 - The outcome statement for the severe asthma stakeholder meeting held on 14 December 2018 is now available.

The PBAC Chair outlined that the objective of the stakeholder meeting was to receive advice and clinical perspectives on the treatment of severe asthma within the context of effective use of biologic medicines. 

The PBAC Chair noted that the meeting provided the opportunity to address concerns raised by sponsors and clinicians in early 2018.

Stakeholders highlighted the importance of the following key issues:

• Reducing exacerbations and OCS use in the severe asthma population
• Having a suitable method to assess patients’ response and/or symptom control
• Re-examining certain aspects of the PBS restriction for biologic medicines to ensure that those most at risk are not excluded.

Read stakeholder meeting report